0% found this document useful (0 votes)
158 views5 pages

Guardant360 Patient Brochure

Uploaded by

Soca Arrel
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
158 views5 pages

Guardant360 Patient Brochure

Uploaded by

Soca Arrel
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 5

PAT I E N T B R O C H U R E

Find treatment options with


the ease of a blood draw

Test. Take Action.


Guardant360® is a blood test that
helps your doctor decide which
therapy may be right for you

Expect your results in about


7 days from receipt at laboratory
7 Your doctor will receive a notification
as soon as your results are ready

Many insurance providers


cover Guardant360 testing
Check with our Client Services
team to see if your insurer is one of them

Contact Client Services


+44 (0) 808 189 5057
THE LE ADER IN COMPREHENSIVE LIQUID BIOPSY clientserviceseurope@guardanthealth.com
Find treatment options Seeing the full picture
For patients with advanced cancers, targeted As a blood test, Guardant360 captures the DNA that is
therapies can provide promising new treatment shed from your tumour.* This provides a comprehensive
options. But a clear genomic picture is needed for overview of your cancer genomics from both your
your doctor to consider your best treatment options. Seeing
primary the and
tumour fullany
picture
metastatic sites.

Traditionally, a tissue biopsy was the only way to As a blood


Your test, Guardant360
report shows yourcaptures the DNA
cancer’s that is
genomic
access this information. The Guardant360 liquid shed from your
alterations tumor. This
detected in provides
the blood. a comprehensive
Associated
biopsy may provide this information with a simple, overviewand
therapies of your
drugscancer
still ingenomics from
clinical trials areboth your
listed where
non-invasive blood draw. primary tumor
available.** Yourand any metastatic
oncologist sites. your results to
will interpret
identify the best
Your report treatment
shows option for
your cancer’s you. alterations
genomic
detected in the blood. Associated FDA-approved
therapies
*Not andshed
all tumours drugs
DNAstill
intointhe
clinical trials are
bloodstream, in listed where
most cancer
available.*
types Your physician
approximately will interpret
90% of tumours shed DNA your
1
. results to
**Not everythe
identify alteration has an associated
best treatment option therapy
for you.or clinical trial.
*Not every alteration has an associated therapy or clinical trial.
1. Zill OA, Banks KC, Fairclough SR, et al. The Landscape of Actionable
Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807
How it works Advanced Cancer Patients. Clinical Cancer Research. 2018.

DAY 7
DAY
DAY11 DAY 7

Guardant360 report
Blood
Bloodsample
sample Sample
Sample released toGuardant360
your doctorreport
received
receivedat
at lab
lab Processing Begins
Processing Begins released to your doctor

Guardant360 reads You and your


doctor review your
WeA will
member of our
verify your eligibility teamand interpretsGuardant360
Client Services
insurance the reads You and your
Bl Bl Guardant360 results
o oo o d arwanw n willcontact
and contact youyou, your insurance cancer DNA and
or out-of-pocket
if your in your
interprets the doctor review your
d D rD expense mayfor
provider, exceed
payment $100 blood
cancer DNA Guardant360 results
in your blood

You deserve to see


the full picture of your
cancer genomics
You deserve to see
the full picture of your
cancer genomics
The right treatment
can make all the
difference

Guardant360 can help


Your doctor may order
Guardant360 examines 70+ clinically-relevant genes
to identify genomic alterations within your cancer’s
DNA while avoiding the complications and delays of
a tissue biopsy. Guardant360 when:
– Some of these genomic alterations may mean that
– Tumour testing of your initial tissue biopsy is
you are likely to respond well to specific drugs
incomplete or inconclusive
– Others may indicate that your cancer is likely to
be resistant to treatment – Your cancer is progressing on the
current treatment
Knowing which alterations are in your cancer helps
your doctor choose the best treatment.
Your doctor can request a
Guardant360 Test Kit

by clicking Order now


on our website at guardanthealth.eu

Easy Billing Process


There you can find additional
resources: When you or a loved one has been diagnosed with
cancer, the last thing you want to worry about is an
unexpected bill amount or confusing paperwork.

That's why Guardant Health offers an easy billing


process with no hidden fees and with our Client
Services team available to support you every step
View the genes included of the way.
on the Guardant360 test
If your hospital or healthcare provider does not
collect your payment for the test, then we offer the
following three options for payment to Guardant
Health directly: Bank Transfer, Credit Card, or
PayPal.

Once your blood sample arrives at our laboratory,


our Client Services team will contact you to help
Check peer-reviewed decide on the best payment option.
publications validating
Guardant360 performance If your insurance provider fully covers the cost of
the Guardant360 test, your doctor will only need
to provide us the insurance authorisation number
and we will then contact your insurer for payment
directly.

Your doctor should advise you on the price of the


test before taking your sample, alternatively please
See limitations of tissue contact our Client Services team who will be
and when Guardant360 happy to help. Test kits are free of charge, and
is indicated payment is collected only upon testing.

Watch videos
on using Guardant360

Questions?
We want to hear from you.
Contact Client Services
+44 (0) 808 189 5057
clientserviceseurope@guardanthealth.com
guardanthealth.eu
®

Test. Take Action.

REC-MKT-EUAA-00006-R3
01.06.2021

You might also like